A phase II cohort study of 160 mg osimertinib NSCLC patients with EGFR T790M and BrMs or LM demonstrated an intracranial ORR of 55% in the BrM patients and intracranial progression was observed in 18.5% of the LM patients [73], suggesting that doubling the dose could be a reasonable strategy for the local control of BrMs and LM. This evidence concerns the gene EGFR and non-small cell lung carcinoma.